1. Home
  2. LTRN vs CRIS Comparison

LTRN vs CRIS Comparison

Compare LTRN & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lantern Pharma Inc.

LTRN

Lantern Pharma Inc.

HOLD

Current Price

$3.60

Market Cap

49.9M

Sector

Health Care

ML Signal

HOLD

Logo Curis Inc.

CRIS

Curis Inc.

HOLD

Current Price

$1.16

Market Cap

14.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LTRN
CRIS
Founded
2013
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
49.9M
14.6M
IPO Year
2020
2000

Fundamental Metrics

Financial Performance
Metric
LTRN
CRIS
Price
$3.60
$1.16
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$25.00
$16.50
AVG Volume (30 Days)
71.4K
114.9K
Earning Date
11-12-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$11,650,000.00
Revenue This Year
N/A
$6.13
Revenue Next Year
N/A
$8.44
P/E Ratio
N/A
N/A
Revenue Growth
N/A
13.56
52 Week Low
$2.55
$1.02
52 Week High
$6.12
$4.50

Technical Indicators

Market Signals
Indicator
LTRN
CRIS
Relative Strength Index (RSI) 47.80 40.13
Support Level $3.72 $1.29
Resistance Level $3.98 $1.41
Average True Range (ATR) 0.27 0.12
MACD 0.04 0.01
Stochastic Oscillator 48.72 23.54

Price Performance

Historical Comparison
LTRN
CRIS

About LTRN Lantern Pharma Inc.

Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.

About CRIS Curis Inc.

Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

Share on Social Networks: